Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
61.36
-0.63 (-1.02%)
At close: Nov 19, 2026, 4:00 PM EST
60.14
-1.22 (-1.99%)
After-hours: Nov 19, 2026, 4:44 PM EST
Eton Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Eton Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $80.75. The average 1-year stock price forecast is 31.60% higher than the current stock price, while the lowest is $80 (+30.38%) and the highest is $82 (+33.64%).
Price Target: $80.75 (+31.60%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Eton Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Buy Maintains $70 → $81 | Buy | Maintains | $70 → $81 | +32.01% | Nov 10, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $78 → $82 | Buy | Maintains | $78 → $82 | +33.64% | Nov 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $68 → $80 | Buy | Reiterates | $68 → $80 | +30.38% | Nov 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $70 → $80 | Buy | Maintains | $70 → $80 | +30.38% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
179.91M
from 79.95M
Increased by 125.03%
Revenue Next Year
286.90M
from 179.91M
Increased by 59.47%
EPS This Year
1.78
from 0.32
Increased by 454.69%
EPS Next Year
3.31
from 1.78
Increased by 86.20%
EPS and Forward PE are based on non-GAAP adjusted numbers.